Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Tuberculosis and Respiratory Diseases ; : 664-669, 2004.
Artigo em Coreano | WPRIM | ID: wpr-106171

RESUMO

Extramedullary plasmacytoma(EMP) comprises 5% of all plasma cell neoplasms and commonly occurs in the upper airway or digestive tract. However, it rarely develops in the lungs. We present a case of primary pulmonary plasmacyotma in a 45 year old man, who presented as an endobronchial mass with a pleural effusion, but without evidence of multiple myeloma. The treatment options for EMP include surgery, surgery and radiotherapy, surgery and chemotherapy or chemotherapy alone. Surgery and radiation therapy appeared to be equally effective forms of treatment. The local recurrence rate was reported to be 30%, with 48% progressing to multiple myeloma, and median survival was reported to be 63-101 months. Our patient was initially treated with melphalan and prednisolone. However the disease progressed, and radiotherapy was combined with chemotherapy. In addition, the chemotherapy regimen was also changed to thalidomide and dexamethasone. The patient did not respond to this treatment regimen and finally died.


Assuntos
Humanos , Pessoa de Meia-Idade , Dexametasona , Tratamento Farmacológico , Trato Gastrointestinal , Pulmão , Melfalan , Mieloma Múltiplo , Neoplasias de Plasmócitos , Plasmocitoma , Derrame Pleural , Prednisolona , Radioterapia , Recidiva , Talidomida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA